Nara Capital
As asset managers, we invest on behalf of third parties. Our fear of losing their money is greater than the fear of losing an opportunity. Our investment style consists of value orientation, specialization and trust, applying our investment criteria in a disciplined way. We invest to transform the companies into industry leaders. With a hands-on approach, Nara invests in assets enhancing its value with a long-term view. We are a highly experienced team with the patience and tenacity required to see deals through, committing our own money. We create value in a sustainable way, investing in a responsible way to generate a positive impact on the community. We analyze each investment in detail in order to create shared value for our investors, partners, customers, suppliers and workers.
Heecap is a non-invasive, tailored electrostimulation technology that maintains respiratory muscle strength in these patients.
Gyala Therapeutics is dedicated to developing innovative CAR-T therapies aimed at treating hematological malignancies, such as leukemia and B cell lymphomas. The company utilizes a gene therapy approach that involves extracting T lymphocytes, a type of white blood cell crucial for immune responses, from the patient through a process called apheresis. These cells are then genetically modified to express a receptor that specifically targets tumor cells. Once reintroduced into the patient's body, the modified T cells are designed to recognize and attack cancerous cells effectively. Gyala Therapeutics' focus on this advanced form of treatment positions it at the forefront of cancer therapeutics, offering new hope to patients battling critical diseases.
Affirma Biotech is a developer of host-directed drugs as broad-spectrum treatments for chronic and severe infectious diseases. The company utilizes host-directed therapy strategies to interfere with host cell factors that are required by a pathogen for replication or persistence. The company engages in the discovery and development of new anti-infective drugs via immunomodulation.
OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.
Diagnostic of preterm birth risk and induction labor success probabilities through the use of torsional ultrasound technology
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.